Exploring the Design & Development of ABBV-969: a Novel STEAP1/PSMA Dual- Targeted ADC for Advanced Prostate Cancer
- Understanding how ADC design is critical to efficacy
- Explaining how heterogeneity is a hallmark of advanced prostate cancer and suitability for bispecific ADC development
- Enhancing breadth and durability of ADC response through dual targeting of two prominent prostate antigens